Accelerating development of engineered T cell therapies in the EU: current regulatory framework for studying multiple product versions and T2EVOLVE recommendations....

MLA

Ammar, Delphine, et al. “Accelerating Development of Engineered T Cell Therapies in the EU: Current Regulatory Framework for Studying Multiple Product Versions and T2EVOLVE Recommendations...” Frontiers in Immunology, Dec. 2023, pp. 1–11. EBSCOhost, https://doi.org/10.3389/fimmu.2023.1280826.

APA

Ammar, D., Schapitz, I., Luu, M., Hudecek, M., Meyer, M., Taps, T., Schröder, B., Ivics, Z., Sanges, C., Franz, P., Koehl, U., Negre, H., Johanna, I., & Awigena-Cook, J. (2023). Accelerating development of engineered T cell therapies in the EU: current regulatory framework for studying multiple product versions and T2EVOLVE recommendations... Frontiers in Immunology, 1–11. https://doi.org/10.3389/fimmu.2023.1280826

Chicago

Ammar, Delphine, Inga Schapitz, Maik Luu, Michael Hudecek, Miriam Meyer, Timmothy Taps, Bernd Schröder, et al. 2023. “Accelerating Development of Engineered T Cell Therapies in the EU: Current Regulatory Framework for Studying Multiple Product Versions and T2EVOLVE Recommendations...” Frontiers in Immunology, December, 1–11. doi:10.3389/fimmu.2023.1280826.